AMENDMENTS TO THE CLAIMS:

Please amend claim 1, add claims 6-10, and cancel claim 2 without prejudice or disclaimer as follows. This listing of claims replaces all prior versions, and listings of claims in the application.

LISTING OF CLAIMS:

1. (Currently Amended) A method for the treatment of ~~glycine-extended gastrin-17-dependent~~ gastrointestinal tumors, whose growth is stimulated by glycine-extended gastrin-17, comprising: administering to a mammal a therapeutically effective amount of an anti-G17 immunogenic composition, wherein the amount of the immunogenic composition administered is sufficient to inhibit physiological effects of gastrin-17, amidated gastrin and glycine-extended gastrin-17.

2. Cancelled.

3. (Previously Presented) The method of claim 1, wherein the gastrointestinal tumors contain gastrin/cholecystokinin B (CCK-B) receptors.

4. (Original) The method of claim 1, wherein the gastrointestinal tumors are colorectal adenocarcinomas.

5. (Original) The method of claim 1, wherein the mammal is a human.

6. (New) The method of claim 1, further comprising:

assaying a serum sample from the mammal to determine the level of extended gastrin 17 to determine a dosage of the composition for neutralization of gastrin-17 and glycine-extended gastrin-17 to inhibit growth of tumor cells.

7. (New) The method of claim 1, further comprising:

monitoring antibody titer levels against glycine-extended glycine-17 and amidated glycine-17; and

administering booster immunizations of the immunogenic composition to maintain an antibody titer effective to neutralize glycine-extended glycine-17 and amidated glycine-17.

8. (New) A method for the treatment of gastrointestinal tumors, whose growth is stimulated by glycine-extended gastrin-17, comprising: administering to a mammal a therapeutically effective amount antibodies against gastrin-17, wherein the amount of antibodies administered is sufficient to inhibit physiological effects of gastrin-17, amidated gastrin and glycine-extended gastrin-17 to effect treatment of the tumor.

9. (New) The method of claim 8, wherein the antibodies are monoclonal antibodies.

10 (New) The method of claim 9, wherein the antibodies are human, humanized or chimeric.